VIDEO: Epcoritamab plus R2 ‘showed potent antitumor activity’ in follicular lymphoma
Click Here to Manage Email Alerts
CHICAGO - In this video, Reid Merryman, MD, discusses updates on a trial testing the combination of epcoritamab, rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma.
When presented at the American Society of Clinical Oncology Meeting, Merryman, instructor in medicine at Harvard Medical School, discussed how epcoritamab (DuoBody-CD3xCD20;Genmab, AbbVie) plus rituximab (Rituxan, Genentech) and lenalidomide (Revlimid, Bristol Myers Squibb), known as R2, showed potent antitumor activity and a manageable safety profile, according to researchers.
“Those three drugs all have non overlapping toxicities and different modes of actions. It was hypothesized that the immunomodulatory effects of lenalidomide might enhance the activity of epcoritamab,” Merryman said.
The epcoritamab plus R2 combination was tested in 110 patients. There were two different dosing frequencies: In arm 2a, epcoritimab was dosed more frequently. In 2b, epcoritimab was dosed less frequently.
“Despite these high-risk features, high response rates were seen. The overall response rate was 98% and the complete response rate was 87%, both of which are quite high in the relapsed-refractory setting. Notably, those high response rates were seen across all different patient subgroups including those high-risk subgroups,” Merryman said.
“These results are very encouraging. We need longer follow-up to see how durable these responses will be, but I think this study adds to a growing number of studies that suggest that bispecific antibodies will be very important drugs in this field, and that this combination in particular may be an attractive way to give bispecific antibodies based on this trial,” Merryman continued.
Collapse
Merryman, R, et al. Abstract 7506. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Read more about
Click Here to Manage Email Alerts